Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Fosamprenavir is a phosphate prodrug that is hydrolysed to amprenavir. Amprenavir inhibits HIV-1 protease, preventing cleavage of viral gag-pol polyproteins and production of mature infectious virions.
Indications / reported uses
Treatment of HIV-1 infection in combination with other antiretroviral agents in adults and eligible paediatric patients; current use depends on resistance profile, drug interactions and national treatment guidelines
Identification source:PubChem record (CID 131536). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Fosamprenavir PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fosamprenavir Permitted Daily Exposure (PDE) report (the Fosamprenavir PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fosamprenavir Occupational Exposure Limit (OEL) report (the Fosamprenavir OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.